BlackRock Acquires Stake In Cardio Diagnostics

Published by
Benzinga

BlackRock (NYSE: BLK) has acquired a minor stake in Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company. In BlackRock’s 13G filing on Feb. 2, they disclosed ownership representing 5.2% of Cardio Diagnostics. Fintel reports that the average one-year price target for Cardio Diagnostics is $6.12, and forecasts range from a low of $4.04 to a high of $8.40. Cardio Diagnostics had Weighted-Average Shares Outstanding (Diluted) of 11.90 million for the most recently reported fiscal quarter, ending Sept. 30, 2023. Cardio Diagnostics’ stock has…

Read More

See also  AI audience row at Sundance sparks walkout, highlights division

Leave a Reply